{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:20:33Z","timestamp":1793413233373,"version":"4.5.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1038\/s41391-024-00906-z","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T14:02:52Z","timestamp":1729173772000},"page":"672-683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey"],"prefix":"10.1038","volume":"28","author":[{"given":"Hannah D.","family":"McManus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5990-298X","authenticated-orcid":false,"given":"Tanya","family":"Dorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6563-4587","authenticated-orcid":false,"given":"Alicia K.","family":"Morgans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7012-1754","authenticated-orcid":false,"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"key":"906_CR1","unstructured":"National Cancer Institute: Cancer stat facts: common cancer sites. 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/common.html."},{"key":"906_CR2","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"906_CR3","unstructured":"National Comprehensive Cancer Network. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Prostate Cancer V.4.2024, \u00a9 National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Available at NCCN.org. 2024."},{"key":"906_CR4","doi-asserted-by":"crossref","unstructured":"Messina C, Giunta EF, Signori A, Rebuzzi SE, Banna GL, Maniam A, et al. Combining PARP inhibitors and androgen receptor signalling inhibitors in metastatic prostate cancer: a quantitative synthesis and meta-analysis. Eur Urol Oncol. 2023;7:179\u201388.","DOI":"10.1016\/j.euo.2023.07.013"},{"key":"906_CR5","doi-asserted-by":"publisher","first-page":"519388","DOI":"10.3389\/fonc.2020.519388","volume":"10","author":"J Chen","year":"2020","unstructured":"Chen J, Ni Y, Sun G, Liao B, Zhang X, Zhao J, et al. Comparison of current systemic combination therapies for metastatic hormone-sensitive prostate cancer and selection of candidates for optimal treatment: a systematic review and Bayesian network meta-analysis. Front Oncol. 2020;10:519388.","journal-title":"Front Oncol"},{"key":"906_CR6","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148\u201359.","journal-title":"J Clin Oncol"},{"key":"906_CR7","unstructured":"Janssen Biotech Inc: ZYTIGA (abiraterone acetate), tablets for oral administration: highlights of prescribing information. 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202379lbl.pdf."},{"key":"906_CR8","unstructured":"Astellas Inc.: XTANDI (enzalutamide) capsules\/tablets, for oral use: highlights of prescribing information. 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/203415s019,213674s006lbl.pdf."},{"key":"906_CR9","unstructured":"Sanofi Aventis US: TAXOTERE (docetaxel) injection, for intravenous use: highlights of prescribing information. 1996. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/020449s086lbl.pdf."},{"key":"906_CR10","unstructured":"Sanofi Aventis US: JEVTANA (cabazitaxel) Injection, 60 mg\/1.5 mL, for intravenous infusion only: highlights of prescribing information. 2010. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/201023s024lbl.pdf."},{"key":"906_CR11","unstructured":"Bayer Healthcare: XOFIGO (radium Ra 223 dichloride) injection, for intravenous use: highlights of prescribing information. 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/203971s016lbl.pdf."},{"key":"906_CR12","unstructured":"Dendreon Corporation: PROVENGE\u00ae (sipuleucel-T) suspension for intravenous infusion: highlights of prescribing information. 2010. https:\/\/www.fda.gov\/media\/78511\/download."},{"key":"906_CR13","unstructured":"Novartis Pharmaceuticals Corporation: PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous use: highlights of prescribing information. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215833s000lbl.pdf."},{"key":"906_CR14","unstructured":"AstraZeneca: LYNPARZA (olaparib) tablets, for oral use: highlights of prescribing information. 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/208558s025lbl.pdf."},{"key":"906_CR15","unstructured":"ZR Pharma: RUBRACA (rucaparib) tablets, for oral use: highlights of prescribing information. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/209115s013lbl.pdf."},{"key":"906_CR16","unstructured":"Janssen Biotech: AKEEGA (niraparib and abiraterone acetate) tablets, for oral use. 2023. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/AKEEGA-pi.pdf."},{"key":"906_CR17","unstructured":"Merck Sharp & Dohme: KEYTRUDA\u00ae (pembrolizumab) injection, for intravenous use: highlights of prescribing information. 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/209115s013lbl.pdf."},{"key":"906_CR18","unstructured":"Pfizer: TALZENNA (talazoparib) capsules, for oral use: prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/211651s010lbl.pdf."},{"key":"906_CR19","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1200\/JCO.23.00985","volume":"41","author":"G Francolini","year":"2023","unstructured":"Francolini G, Gaetano Allegra A, Detti B, Di Cataldo V, Caini S, Bruni A, et al. Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO). J Clin Oncol. 2023;41:5561\u20138. Jco2300985","journal-title":"J Clin Oncol"},{"key":"906_CR20","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995\u20132005.","journal-title":"N Engl J Med"},{"key":"906_CR21","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"key":"906_CR22","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147\u201354.","journal-title":"Lancet"},{"key":"906_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323.","journal-title":"N Engl J Med"},{"key":"906_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411\u201322.","journal-title":"N Engl J Med"},{"key":"906_CR25","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Eng J Med. 2021;385:1091\u2013103.","journal-title":"N Eng J Med"},{"key":"906_CR26","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1094\u2013108.","journal-title":"Lancet Oncol"},{"key":"906_CR27","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1200\/JCO.20.01035","volume":"38","author":"W Abida","year":"2020","unstructured":"Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol. 2020;38:3763\u201372.","journal-title":"J Clin Oncol"},{"key":"906_CR28","doi-asserted-by":"crossref","unstructured":"Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402:291\u2013303.","DOI":"10.1016\/S0140-6736(23)01055-3"},{"key":"906_CR29","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","volume":"41","author":"KN Chi","year":"2023","unstructured":"Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J Clin Oncol. 2023;41:3339\u201351.","journal-title":"J Clin Oncol"},{"key":"906_CR30","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1007\/s00345-019-02717-7","volume":"37","author":"L Triggiani","year":"2019","unstructured":"Triggiani L, Mazzola R, Magrini SM, Ingrosso G, Borghetti P, Trippa F, et al. Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World J Urol. 2019;37:2631\u20137.","journal-title":"World J Urol"},{"key":"906_CR31","doi-asserted-by":"publisher","first-page":"e0233260","DOI":"10.1371\/journal.pone.0233260","volume":"15","author":"LS Graham","year":"2020","unstructured":"Graham LS, Montgomery B, Cheng HH, Yu EY, Nelson PS, Pritchard C, et al. Mismatch repair deficiency in metastatic prostate cancer: response to PD-1 blockade and standard therapies. PLoS ONE. 2020;15:e0233260.","journal-title":"PLoS ONE"},{"key":"906_CR32","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Flechon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet. 2022;399:1695\u2013707.","journal-title":"Lancet"},{"key":"906_CR33","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/cncr.28518","volume":"120","author":"S Badrising","year":"2014","unstructured":"Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P, et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer. 2014;120:968\u201375.","journal-title":"Cancer"},{"key":"906_CR34","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1093\/annonc\/mdt138","volume":"24","author":"KL Noonan","year":"2013","unstructured":"Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013;24:1802\u20137.","journal-title":"Ann Oncol"},{"key":"906_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.euo.2023.05.002","volume":"7","author":"J Dodkins","year":"2024","unstructured":"Dodkins J, Nossiter J, Cook A, Payne H, Clarke N, van der Meulen J, et al. Does research from clinical trials in metastatic hormone-sensitive prostate cancer treatment translate into access to treatments for patients in the \u201creal world\u201d? a systematic review. Eur Urol Oncol. 2024;7:14\u201324.","journal-title":"Eur Urol Oncol"},{"key":"906_CR36","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","volume":"38","author":"ND Shore","year":"2021","unstructured":"Shore ND, Lalibert\u00e9 F, Ionescu-Ittu R, Yang L, Mahendran M, Lejeune D, et al. Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors. Adv Ther. 2021;38:4520\u201340.","journal-title":"Adv Ther"},{"key":"906_CR37","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1200\/JCO.2013.54.8404","volume":"32","author":"E Basch","year":"2014","unstructured":"Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. J Clin Oncol. 2014;32:3436\u201348.","journal-title":"J Clin Oncol"},{"key":"906_CR38","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to advanced prostate cancer: AUA\/SUO guidelines (2023). J Urol. 2023;209:1082\u201390.","journal-title":"J Urol"},{"key":"906_CR39","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","volume":"34","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Gillessen S. Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents. Ann Oncol. 2023;34:557\u201363.","journal-title":"Ann Oncol"},{"key":"906_CR40","unstructured":"European Association of Urology: Prostate Cancer. 2024. https:\/\/uroweb.org\/guidelines\/prostate-cancer."},{"key":"906_CR41","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.21037\/tau-20-1341","volume":"10","author":"MC Dror","year":"2021","unstructured":"Dror MC, Chi KN, Khalaf DJ. Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer-a narrative review. Transl Androl Urol. 2021;10:3931\u201345.","journal-title":"Transl Androl Urol"},{"key":"906_CR42","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.eururo.2017.09.022","volume":"73","author":"P Lavaud","year":"2018","unstructured":"Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, et al. Anticancer activity and tolerance of treatments received beyond progression in men treated upfront with androgen deprivation therapy with or without docetaxel for metastatic castration-na\u00efve prostate cancer in the GETUG-AFU 15 phase 3 trial. Eur Urol. 2018;73:696\u2013703.","journal-title":"Eur Urol"},{"key":"906_CR43","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","volume":"34","author":"S Halabi","year":"2016","unstructured":"Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol. 2016;34:1652\u20139.","journal-title":"J Clin Oncol"},{"key":"906_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.eururo.2013.09.024","volume":"65","author":"GR Pond","year":"2014","unstructured":"Pond GR, Sonpavde G, de Wit R, Eisenberger MA, Tannock IF, Armstrong AJ. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol. 2014;65:3\u20136.","journal-title":"Eur Urol"},{"key":"906_CR45","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.annonc.2021.03.205","volume":"32","author":"M Annala","year":"2021","unstructured":"Annala M, Fu S, Bacon JVW, Sipola J, Iqbal N, Ferrario C, et al. Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. Ann Oncol. 2021;32:896\u2013905.","journal-title":"Ann Oncol"},{"key":"906_CR46","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.euo.2020.05.004","volume":"4","author":"MP Deek","year":"2021","unstructured":"Deek MP, Taparra K, Phillips R, Velho PI, Gao RW, Deville C, et al. Metastasis-directed therapy prolongs efficacy of systemic therapy and improves clinical outcomes in oligoprogressive castration-resistant prostate cancer. Eur Urol Oncol. 2021;4:447\u201355.","journal-title":"Eur Urol Oncol"},{"key":"906_CR47","doi-asserted-by":"crossref","unstructured":"Patel P, Dreibe S, Attard G, Cole A, Frew J, Guevara J, et al. Primary endpoint analysis of TRAP, first prospective Phase II trial of SBRT to oligoprogressive disease prostate cancer (NCT03644303). ESTRO:poster 3381, 2024.","DOI":"10.1016\/S0167-8140(24)03363-2"},{"key":"906_CR48","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1093\/annonc\/mdy406","volume":"29","author":"AJ Armstrong","year":"2018","unstructured":"Armstrong AJ, Lin P, Higano CS, Sternberg CN, Sonpavde G, Tombal B, et al. Development and validation of a prognostic model for overall survival in chemotherapy-na\u00efve men with metastatic castration-resistant prostate cancer. Ann Oncol. 2018;29:2200\u20137.","journal-title":"Ann Oncol"},{"key":"906_CR49","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1093\/annonc\/mdv594","volume":"27","author":"KN Chi","year":"2016","unstructured":"Chi KN, Kheoh T, Ryan CJ, Molina A, Bellmunt J, Vogelzang NJ, et al. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Ann Oncol. 2016;27:454\u201360.","journal-title":"Ann Oncol"},{"key":"906_CR50","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1200\/JCO.22.02661","volume":"41","author":"S Halabi","year":"2023","unstructured":"Halabi S, Yang Q, Roy A, Luo B, Araujo JC, Logothetis C, et al. External validation of a prognostic model of overall survival in men with chemotherapy-naive metastatic castration-resistant prostate cancer. J Clin Oncol. 2023;41:2736\u201346.","journal-title":"J Clin Oncol"},{"key":"906_CR51","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375:443\u201353.","journal-title":"N Engl J Med"},{"key":"906_CR52","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215\u201328.","journal-title":"Cell"},{"key":"906_CR53","first-page":"PO.17.00029","volume":"2017","author":"W Abida","year":"2017","unstructured":"Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol. 2017;2017:PO.17.00029.","journal-title":"JCO Precis Oncol"},{"key":"906_CR54","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.2217\/fon-2021-0153","volume":"17","author":"N Shore","year":"2021","unstructured":"Shore N, Ionescu-Ittu R, Yang L, Laliberte F, Mahendran M, Lejeune D, et al. Real-world genetic testing patterns in metastatic castration-resistant prostate cancer. Future Oncol. 2021;17:2907\u201321.","journal-title":"Future Oncol"},{"key":"906_CR55","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.3390\/cancers14071728","volume":"14","author":"F Ionescu","year":"2022","unstructured":"Ionescu F, Zhang J, Wang L. Clinical applications of liquid biopsy in prostate cancer: from screening to predictive biomarker. Cancers (Basel). 2022;14:1728.","journal-title":"Cancers (Basel)"},{"key":"906_CR56","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1001\/jamaoncol.2020.5161","volume":"7","author":"K Jensen","year":"2021","unstructured":"Jensen K, Konnick EQ, Schweizer MT, Sokolova AO, Grivas P, Cheng HH, et al. Association of clonal hematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference. JAMA Oncol. 2021;7:107\u201310.","journal-title":"JAMA Oncol"},{"key":"906_CR57","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, et al. Rucaparib or physician\u2019s choice in metastatic prostate cancer. N Engl J Med. 2023;388:719\u201332.","journal-title":"N Engl J Med"},{"key":"906_CR58","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091\u2013102.","journal-title":"N Engl J Med"},{"key":"906_CR59","doi-asserted-by":"publisher","first-page":"eaam7479","DOI":"10.1126\/scisignal.aam7479","volume":"10","author":"L Li","year":"2017","unstructured":"Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, et al. Androgen receptor inhibitor-induced \u201cBRCAness\u201d and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017;10:eaam7479.","journal-title":"Sci Signal"},{"key":"906_CR60","doi-asserted-by":"crossref","unstructured":"Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Mototsugu O, Shore N, Loredo E, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evidence. 2022;1:EVIDoa2200043.","DOI":"10.1056\/EVIDoa2200043"},{"key":"906_CR61","unstructured":"AstraZeneca: Update on FDA Advisory Committee vote on Lynparza plus abiraterone for metastatic castration-resistant prostate cancer. 2023. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/odac-vote-on-lynparza-combo-in-prostate-cancer.html."},{"key":"906_CR62","doi-asserted-by":"publisher","first-page":"5004","DOI":"10.1200\/JCO.2023.41.16_suppl.5004","volume":"41","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Azad A, Matsubara N, Carles J, Fay AP, De Giorgi U, et al. TALAPRO-2: Phase 3 study of talazoparib (TALA)\u2009+\u2009enzalutamide (ENZA) versus placebo (PBO)\u2009+\u2009ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations. J Clin Oncol. 2023;41:5004.","journal-title":"J Clin Oncol"},{"key":"906_CR63","doi-asserted-by":"publisher","first-page":"S1326","DOI":"10.1016\/j.annonc.2023.10.087","volume":"34","author":"KNN Chi","year":"2023","unstructured":"Chi KNN, Castro E, Attard G, Smith MR, Sandhu SK, Efstathiou E, et al. LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: three-year update and final analysis (FA) of MAGNITUDE. Ann Oncol. 2023;34:S1326.","journal-title":"Ann Oncol"},{"key":"906_CR64","unstructured":"Pfizer: TALZENNA (talazoparib) capsules, for oral use: summary of product characteristics. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/talzenna-epar-product-information_en.pdf."},{"key":"906_CR65","unstructured":"AstraZeneca: LYNPARZA (olaparib) tablets, for oral use: summary of product characteristics. 2015. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lynparza-epar-product-information_en.pdf."},{"key":"906_CR66","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1200\/JCO.23.02105","volume":"42","author":"J Fallah","year":"2024","unstructured":"Fallah J, Xu J, Weinstock C, Gao X, Heiss BL, Maguire WF, et al. Efficacy of poly(ADP-ribose) polymerase inhibitors by individual genes in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer: a US Food and Drug Administration pooled analysis. J Clin Oncol. 2024;42:1687\u201398.","journal-title":"J Clin Oncol"},{"key":"906_CR67","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1172\/JCI121924","volume":"128","author":"D Nava Rodrigues","year":"2018","unstructured":"Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Investig. 2018;128:4441\u201353.","journal-title":"J Clin Investig"},{"key":"906_CR68","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","volume":"5","author":"W Abida","year":"2019","unstructured":"Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 2019;5:471\u20138.","journal-title":"JAMA Oncol"},{"key":"906_CR69","unstructured":"Food and Drug Administration: FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication. 2017. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication."},{"key":"906_CR70","unstructured":"GlaxoSmithKline: JEMPERLI (dostarlimab-gxly) injection, for intravenous use: summary of product characteristics. 2021. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Jemperli\/pdf\/JEMPERLI-PI-MG.PDF."},{"key":"906_CR71","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804.","journal-title":"Lancet"},{"key":"906_CR72","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1200\/JCO.2022.40.16_suppl.5002","volume":"40","author":"P Kuo","year":"2022","unstructured":"Kuo P, Hesterman J, Rahbar K, Kendi AT, Wei XX, Fang B, et al. [68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy. J Clin Oncol. 2022;40:5002.","journal-title":"J Clin Oncol"},{"key":"906_CR73","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","volume":"25","author":"MS Hofman","year":"2023","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, et al. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2023;25:99\u2013107.","journal-title":"Lancet Oncol"},{"key":"906_CR74","unstructured":"Food and Drug Administration: FDA approves larotrectinib for solid tumors with NTRK gene fusions. 2018. https:\/\/www.fda.gov\/drugs\/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions."},{"key":"906_CR75","unstructured":"Food and Drug Administration: FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC. 2019. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc,"},{"key":"906_CR76","unstructured":"Food and Drug Administration: FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation. 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid."},{"key":"906_CR77","unstructured":"Food and Drug Administration: FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors. 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-solid-tumors."},{"key":"906_CR78","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1470-2045(12)70537-5","volume":"14","author":"PL Kellokumpu-Lehtinen","year":"2013","unstructured":"Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, et al. 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol. 2013;14:117\u201324.","journal-title":"Lancet Oncol"},{"key":"906_CR79","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1001\/jamaoncol.2023.4255","volume":"9","author":"S Oudard","year":"2023","unstructured":"Oudard S, Ratta R, Voog E, Barthelemy P, Thiery-Vuillemin A, Bennamoun M, et al. Biweekly vs triweekly cabazitaxel in older patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 2023;9:1629\u201338.","journal-title":"JAMA Oncol"},{"key":"906_CR80","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1007\/s00259-021-05618-3","volume":"49","author":"S Satapathy","year":"2022","unstructured":"Satapathy S, Mittal BR, Sood A, Das CK, Mavuduru RS, Goyal S, et al. (177)Lu-PSMA-617 versus docetaxel in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial. Eur J Nucl Med Mol Imaging. 2022;49:1754\u201364.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"906_CR81","doi-asserted-by":"publisher","first-page":"S1324","DOI":"10.1016\/j.annonc.2023.10.085","volume":"34","author":"O Sartor","year":"2023","unstructured":"Sartor O, Castellano Gauna DE, Herrmann K, de Bono JS, Shore ND, Chi KNN, et al. LBA13 phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore). Ann Oncol. 2023;34:S1324\u2013S1325.","journal-title":"Ann Oncol"},{"key":"906_CR82","unstructured":"Novartis Pharmaceuticals Corporation: Press Release. Novartis Pluvicto\u2122 shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting. 2023. https:\/\/www.novartis.com\/news\/media-releases\/novartis-pluvictotm-shows-clinically-meaningful-and-highly-statistically-significant-rpfs-benefit-patients-psma-positive-metastatic-castration-resistant-prostate-cancer-pre-taxane-setting."},{"key":"906_CR83","unstructured":"UroToday: Press Release. ASCO 2024: PSMAfore: HRQoL and pain in a phase 3 study of 177Lu-PSMA-617 in taxane-na\u00efve patients with mCRPC. 2024. https:\/\/www.urotoday.com\/conference-highlights\/asco-2024\/asco-2024-prostate-cancer\/152475-asco-2024-psmafore-hrqol-and-pain-in-a-phase-3-study-of-177lu-psma-617-in-taxane-naive-patients-with-mcrpc.html."},{"key":"906_CR84","doi-asserted-by":"publisher","first-page":"S1325","DOI":"10.1016\/j.annonc.2023.10.086","volume":"34","author":"L Emmett","year":"2023","unstructured":"Emmett L, Subramaniam S, Crumbaker M, Joshua AM, Weickhardt AJ, Lee ST, et al. LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): a randomised, phase II trial: ENZA-p (ANZUP 1901). Ann Oncol. 2023;34:S1325.","journal-title":"Ann Oncol"},{"key":"906_CR85","unstructured":"ClinicalTrials.gov: An international prospective open-label, randomized, phase III study comparing 177Lu-PSMA-617 in combination with SoC, versus SoC alone, in adult male patients with mHSPC (PSMAddition). NCT04720157. 2024. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04720157."},{"key":"906_CR86","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231157632","volume":"15","author":"A Jang","year":"2023","unstructured":"Jang A, Kendi AT, Sartor O. Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials. Ther Adv Med Oncol. 2023;15:17588359231157632.","journal-title":"Ther Adv Med Oncol"},{"key":"906_CR87","unstructured":"ClinicalTrials.gov: Study of I-131-1095 radiotherapy in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer who are chemotherapy naive and have progressed on abiraterone (ARROW). NCT03939689. 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03939689."},{"key":"906_CR88","doi-asserted-by":"publisher","first-page":"S1185","DOI":"10.1016\/j.annonc.2022.07.1886","volume":"33","author":"AR Hansen","year":"2022","unstructured":"Hansen AR, Probst S, Tutrone RF, Osman MM, Delpassand ES, Nordquist LT, et al. 1400P Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration resistant prostate cancer (mCRPC): initial results from SPLASH. Ann Oncol. 2022;33:S1185.","journal-title":"Ann Oncol"},{"key":"906_CR89","unstructured":"ClinicalTrials.gov: 177Lu-PSMA-I&T for metastatic castration-resistant prostate cancer. NCT05204927. 2024. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05204927."},{"key":"906_CR90","unstructured":"ClinicalTrials.gov: Pembrolizumab plus 177Lu-PSMA-617 in patients with castration resistant prostate cancer. NCT05766371. 2024. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05766371."},{"key":"906_CR91","unstructured":"ClinicalTrials.gov: Dose-escalation study of cabozantinib in combination with lutetium-177 (177Lu)-PSMA-617 in patients with metastatic castration-resistant prostate cancer (CaboLu). NCT05613894. 2024. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05613894."},{"key":"906_CR92","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","volume":"26","author":"DR Berthold","year":"2008","unstructured":"Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242\u20135.","journal-title":"J Clin Oncol"},{"key":"906_CR93","doi-asserted-by":"publisher","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","volume":"25","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, et al. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res. 2019;25:7448\u201354.","journal-title":"Clin Cancer Res"},{"key":"906_CR94","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1158\/1078-0432.CCR-21-1483","volume":"28","author":"TB Dorff","year":"2022","unstructured":"Dorff TB, Narayan V, Forman SJ, Zang PD, Fraietta JA, June CH, et al. Novel redirected t-cell immunotherapies for advanced prostate cancer. Clin Cancer Res. 2022;28:576\u201384.","journal-title":"Clin Cancer Res"},{"key":"906_CR95","unstructured":"Exelixis I: Press Release. Exelixis and Ipsen announce positive results from phase 3 CONTACT-02 pivotal trial evaluating cabozantinib in combination with atezolizumab in metastatic castration-resistant prostate cancer. 2023. https:\/\/ir.exelixis.com\/news-releases\/news-release-details\/exelixis-and-ipsen-announce-positive-results-phase-3-contact-02."},{"key":"906_CR96","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.1158\/1078-0432.CCR-18-0937","volume":"24","author":"G Boysen","year":"2018","unstructured":"Boysen G, Rodrigues DN, Rescigno P, Seed G, Dolling D, Riisnaes R, et al. SPOP-mutated\/CHD1-deleted lethal prostate cancer and abiraterone sensitivity. Clin Cancer Res. 2018;24:5585\u201393.","journal-title":"Clin Cancer Res"},{"key":"906_CR97","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.eururo.2014.10.027","volume":"67","author":"R Ferraldeschi","year":"2015","unstructured":"Ferraldeschi R, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P, et al. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol. 2015;67:795\u2013802.","journal-title":"Eur Urol"},{"key":"906_CR98","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","volume":"25","author":"H Beltran","year":"2019","unstructured":"Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, et al. The role of lineage plasticity in prostate cancer therapy resistance. Clin Cancer Res. 2019;25:6916\u201324.","journal-title":"Clin Cancer Res"},{"key":"906_CR99","doi-asserted-by":"crossref","unstructured":"Akaza H, Procopio G, Pripatnanont C, Facchini G, Fava S, Wheatley D, et al. Metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy: treatment patterns from the PROXIMA prospective registry. J Glob Oncol. 2018;4:1\u201312.","DOI":"10.1200\/JGO.18.00009"},{"key":"906_CR100","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2012","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2012;368:138\u201348.","journal-title":"N Engl J Med"},{"key":"906_CR101","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983\u201392.","journal-title":"Lancet Oncol"},{"key":"906_CR102","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152\u201360.","journal-title":"Lancet Oncol"},{"key":"906_CR103","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"Beer","year":"2014","unstructured":"Beer, Armstrong TM, Rathkopf DE AJ, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333.","journal-title":"N Engl J Med"},{"key":"906_CR104","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","volume":"381","author":"R de Wit","year":"2019","unstructured":"de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wulfing C, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381:2506\u201318.","journal-title":"N Engl J Med"},{"key":"906_CR105","doi-asserted-by":"crossref","unstructured":"Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, et al. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med 2024;30:257\u201364.","DOI":"10.1038\/s41591-023-02704-x"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-024-00906-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-024-00906-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-024-00906-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:03:19Z","timestamp":1756893799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-024-00906-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":105,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["906"],"URL":"https:\/\/doi.org\/10.1038\/s41391-024-00906-z","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,17]]},"assertion":[{"value":"21 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HDM has no conflicts of interest to disclose. TD has received writing support from Pfizer, and has personal consulting or advising relationships with AstraZeneca, Bayer, Janssen Pharmaceuticals, and Sanofi. AM has a consulting relationship with Astellas, AstraZeneca, Bayer, Janssen Pharmaceuticals, Exelixis, Myovant, Merck, Novartis, Pfizer, Telix, and Sanofi. Research collaborations and\/or support was received from Astellas, Bayer, Myovant, Pfizer, and Sanofi. OS has received grants or contracts from Advanced Accelerator Applications, Amgen, AstraZeneca, Bayer, Constellation, Endocyte, Invitae, Janssen Pharmaceuticals, Lantheus, Merck, Progenics Pharmaceuticals Inc., and Teneobio; has received consulting fees from Advanced Accelerator Applications, Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics, Bavarian Nordic, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis, Constellation, Dendreon, EMD Serono, Fusion, Isotopen Technologien Meunchen, Janssen Pharmaceuticals, Myovant, Myriad, Noria Therapeutics, Novartis, Noxopharm, Progenics Pharmaceuticals, Inc., POINT Biopharma Global Inc., Pfizer, Sanofi, Teneobio, Telix, and Theragnostics; has participated on data safety monitoring boards or advisory boards for AstraZeneca, Janssen Pharmaceuticals, Pfizer, and Myovant; and holds stock or stock options in Clarity Pharmaceuticals, Noria Therapeutics, Eli Lilly, Clovis, GlaxoSmithKline, AbbVie, Cardinal Health, and United Health Group. NS has personal consulting or advising relationships with Astellas, Dendreon, Janssen Pharmaceuticals, Bayer, Myriad, MDxHealth, Tolmar, Molvant, Pfizer, AstraZeneca, Merck, Genentech, Pfizer, Urogen, Guardant, Myovant, AbbVie, Amgen, Bristol Myers Squibb, Boston Scientific, Clovis Oncology, Exact Imaging, FerGene, Foundation Medicine, GConcology, Invitae, Nymox, Propella, Sanofi Genzyme, Sesen Bio, Exact Sciences, Pacific Edge, Cold Genesys, Genesis Care, Alessa, Akido, Arquer, Asleris, Clarity, Clovis, Ferring, ImmunityBio, Incyte, Lantheus, Eli Lilly, Minomic, NGM, Nonagen, Novartis, Pacific Edge, Photocure, PlatformQ, Profound, Promaxo, Protara, Speciality Networks, Telix, Vaxllon, Vessi, FIZe Medical, Accord, ANTeV, Bioprotect, Aura Biosciences, CG Oncology, Palette Life, and PREVIEW; and holds a leadership position with Alessa and Photocure. AJA received research support (to Duke) from Astellas, Pfizer, Bayer, Janssen Pharmaceuticals, Dendreon, BMS, AstraZeneca, Merck, Forma, Celgene, Amgen, and Novartis; and has personal consulting or advising relationships with Astellas, Epic Sciences, Pfizer, Bayer, Janssen Pharmaceuticals, Dendreon, BMS, AstraZeneca, Merck, Forma, Celgene, Clovis, Exact Sciences, Myovant, Exelixis, GoodRx, and Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}